LEUKOCARE grants license to US vaccine company PaxVax
LEUKOCARE AG, Germany, and PaxVax, Inc., USA, today announced that both partners have entered into a licensing agreement granting PaxVax access to LEUKOCARE’s proprietary SPS® formulation technology platform for the clinical development and subsequent commercialization of one of PaxVax’s live viral vaccine products. The licensing agreement provides to PaxVax exclusive access to two product-specific pharmaceutical … Skaityti toliau